AB Science S.A. (OTCMKTS:ABSCF) Short Interest Down 66.7% in January

AB Science S.A. (OTCMKTS:ABSCF) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 500 shares, a decline of 66.7% from the January 15th total of 1,500 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

AB Science Price Performance

ABSCF opened at $1.57 on Friday. AB Science has a fifty-two week low of $0.80 and a fifty-two week high of $1.57. The company’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $1.01.

About AB Science

AB Science SA, a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19.